Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$267000.0.

  • Kymera Therapeutics' Change in Account Payables fell 39021.74% to -$267000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$988000.0, marking a year-over-year decrease of 15714.29%. This contributed to the annual value of -$307000.0 for FY2024, which is 11506.38% down from last year.
  • Per Kymera Therapeutics' latest filing, its Change in Account Payables stood at -$267000.0 for Q3 2025, which was down 39021.74% from -$4.1 million recorded in Q2 2025.
  • Kymera Therapeutics' Change in Account Payables' 5-year high stood at $4.2 million during Q3 2022, with a 5-year trough of -$4.1 million in Q2 2025.
  • Moreover, its 5-year median value for Change in Account Payables was -$145000.0 (2021), whereas its average is $81842.1.
  • The largest annual percentage gain for Kymera Therapeutics' Change in Account Payables in the last 5 years was 512266.67% (2025), contrasted with its biggest fall of 1343225.81% (2025).
  • Over the past 5 years, Kymera Therapeutics' Change in Account Payables (Quarter) stood at -$1.0 million in 2021, then plummeted by 101.17% to -$2.1 million in 2022, then surged by 174.03% to $1.5 million in 2023, then plummeted by 132.98% to -$505000.0 in 2024, then soared by 47.13% to -$267000.0 in 2025.
  • Its Change in Account Payables stands at -$267000.0 for Q3 2025, versus -$4.1 million for Q2 2025 and $3.9 million for Q1 2025.